|
Sanofi announced an evolution of its executive committee, bringing together a focused leadership team across its businesses, scientific organization and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter.
Effective September 1, 2026, Sanofi's executive committee will comprise:
- François Roger, executive vice president, finance
- Paulo Fontoura, executive vice president, head of research & development
- Manuela Buxo, executive vice president, specialty care
- Thomas Triomphe, executive vice president, vaccines
- Thomas Grenier, executive vice president, general medicines
- Brendan O’Callaghan, executive vice president, manufacturing & supply
- Jamie Haney, executive vice president, general counsel
- Véronique Jaillet, executive vice president, chief people officer, ad interim
Emmanuel Frenehard, head of digital and Audrey Duval, head of corporate affairs and president of Sanofi France, will continue to report directly to Belén Garijo, Sanofi’s CEO.
Madeleine Roach, currently head of business operations, will become president and country lead of Sanofi Germany, Switzerland and Austria. Her current responsibilities, which focus on optimizing enterprise business services, will be integrated into the finance function. Finance’s expanded remit will also include Global Partnering and Business Development, helping drive a more integrated approach across business development and mergers & acquisitions.
Thomas Triomphe will also assume responsibility for China, alongside his role as executive vice president, vaccines.
Olivier Charmeil, currently executive vice president, general medicines, will transition to strategic projects advisor to the CEO. Throughout his career, Olivier has helped shape the company across a succession of leadership roles, with a deep and enduring commitment to its people, its business and the patients it serves. Roy Papatheodorou, currently executive vice president, general counsel, has decided to leave the organization to pursue external opportunities after over four years with the company, during which he has brought outstanding leadership and contributions which went beyond his role as general counsel.
“This executive committee brings together experienced professionals who will work together to help shape our future direction, make disciplined choices, execute them with focus, and ensure we continue to deliver for our patients, our people and all our stakeholders. I would like to thank all those who have contributed to Sanofi’s success and those who will continue to shape its future. I am deeply grateful for their leadership, commitment and dedication, and I wish everyone every success for the future," said Belén Garijo, chief executive officer of Sanofi.
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. The company apply its deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.
|